Clinical Trial Update: This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight [Phase 2]

View source ↗

Summary

A Phase 2 multi-centre, platform trial in Chinese participants with obesity/overweight is being conducted by AstraZeneca; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Snippet

Sponsor: AstraZeneca | Conditions: Obesity/Overweight | Phase 2 | Status: RECRUITING